consistent with this, the increasing complexity of drug improvement, specially in parts like oncology and unusual ailments, necessitates larger and much more advanced period III trials. This complexity consists of the need for specialized supplies, individual-centric techniques, and adaptive trial patterns. On top of that, the desire for section II